Inspira™ Technologies is Developing the VORTX™ Blood Oxygenator, a Unique Technology for Saturating Blood With Oxygen and Removing Carbon Dioxide

Friday, May 12, 2023

“Inspira Technologies” , a company aiming to revolutionize acute respiratory care, today announced the development of the VORTXTM Blood Oxygenator, an Augmented Respiration Technology based on a new breakthrough technological approach, being designed with the intent to imitate the function of the lung, by efficiently saturating the blood with oxygen and removing carbon dioxide.

The VORTXTM Blood Oxygenator, which is under development, has the potential to revolutionize the perfusionists systems market, currently valued at $1.16 billion in 20231, targeting ~2 million extracorporeal procedures performed annually including open-heart surgeries and extracorporeal membrane oxygenation (“ECMO”) treatment2. The Company anticipates that this market segment may grow substantially with the additional market opportunity represented by the new treatment category potentially created by our flagship INSPIRATM ART.

The VORTXTM Blood Oxygenator is being designed to improve hemodynamic performance and reduce oxygenator failure. The current blood oxygenator market3 is based upon hollow fiber membrane technology, associated with medical complications including device failure, coagulation (clotting) and hemolysis (damage or destruction of red blood cells), which induces risks and impacts patient outcomes.

The VORTXTM Blood Oxygenator is being developed as an independent stand-alone disposable unit that will also be compatible with our flagship INSPIRATM ART system and ALICETM device. Upon completion of development and testing of the VORTXTM Blood Oxygenator, the unit is expected is to be submitted to the U.S. Food and Drug Administration (FDA) for regulatory review and approval.

Dr. Daniella Yeheskely-Hayon, Inspira Technologies’ Chief Technology Officer, stated:

“Having vast experience in blood oxygenation development, my team and I are excited to lead the development of the revolutionary VORTXTM Blood Oxygenator. Inspira Technologies’ highly advanced testing laboratories are the core to the development of this new technological approach. Currently, available blood oxygenators on the market are based on the same hollow fiber membrane technology. Our VORTX™ focuses on a totally new technological approach.”


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress